These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 23658612)
1. Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice. Yang L; Niu H; Gao X; Wang Q; Han G; Cao L; Cai C; Weiler J; Yin H PLoS One; 2013; 8(4):e61584. PubMed ID: 23658612 [TBL] [Abstract][Full Text] [Related]
2. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Yin H; Lu Q; Wood M Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354 [TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089 [TBL] [Abstract][Full Text] [Related]
4. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro. Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454 [TBL] [Abstract][Full Text] [Related]
5. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998 [TBL] [Abstract][Full Text] [Related]
6. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy. Cao L; Han G; Gu B; Yin H PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558 [TBL] [Abstract][Full Text] [Related]
7. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers. Williams JH; Sirsi SR; Latta DR; Lutz GJ Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666 [TBL] [Abstract][Full Text] [Related]
8. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Kendall GC; Mokhonova EI; Moran M; Sejbuk NE; Wang DW; Silva O; Wang RT; Martinez L; Lu QL; Damoiseaux R; Spencer MJ; Nelson SF; Miceli MC Sci Transl Med; 2012 Dec; 4(164):164ra160. PubMed ID: 23241744 [TBL] [Abstract][Full Text] [Related]
9. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results. van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725 [TBL] [Abstract][Full Text] [Related]
10. Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development. Wu B; Benrashid E; Lu P; Cloer C; Zillmer A; Shaban M; Lu QL PLoS One; 2011; 6(5):e19906. PubMed ID: 21611204 [TBL] [Abstract][Full Text] [Related]
11. Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. Kemaladewi DU; Hoogaars WM; van Heiningen SH; Terlouw S; de Gorter DJ; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; ten Dijke P; 't Hoen PA BMC Med Genomics; 2011 Apr; 4():36. PubMed ID: 21507246 [TBL] [Abstract][Full Text] [Related]
12. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy. van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788 [TBL] [Abstract][Full Text] [Related]